Avalon GloboCare Reports Q3 2025 Progress with KetoAir™, Holistic Health Initiatives, and International Expansion
Rhea-AI Summary
Avalon GloboCare (NASDAQ: ALBT) reported Q3 2025 progress for its KetoAir™ breathalyzer, highlighting a UK commercial launch on Sept 1, 2025, presentation at the London Health Optimization Summit on Sept 13–14, 2025, and a Nevada first‑responder program started in August 2025.
The four‑month Nevada POOL/PACT Holistic Health Reset enrolled 50 first responders using KetoAir™ for daily ketone monitoring; October mid‑program data showed individual metabolic improvements. KetoAir™ is FDA‑registered (Reg. No. 3026284320), measures breath acetone (BrAce), and is manufactured by Qi Diagnostics; device apps are available on Apple App Store and Google Play.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ALBT declined 8.11%, reflecting a notable negative market reaction. Argus tracked a peak move of +3.1% during that session. Argus tracked a trough of -17.6% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $615K from the company's valuation, bringing the market cap to $7M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ALBT’s -13.21% move occurred as sector peers NYC, LRHC, and GBR also appeared in momentum scans, all moving down between about -4.61% and -6.20%, suggesting broader sector pressure rather than a purely idiosyncratic move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | KetoAir progress update | Positive | -8.1% | Reported Q3 KetoAir™ progress including UK launch and Nevada program data. |
| Aug 28 | International expansion | Positive | +2.9% | Announced KetoAir™ UK online launch starting September 1, 2025. |
| Jul 28 | Distribution agreement | Positive | +30.8% | Signed Saga Health distribution agreement for KetoAir™ targeting first responders. |
| Jul 14 | Patent issuance | Positive | +6.3% | Secured Hong Kong patent for bispecific CAR-T and CAR-NK technology. |
| Jun 26 | New product collaboration | Positive | +0.9% | Entered agreement with Qi Diagnostics to co-develop cannabis breathalyzer. |
Recent news has been largely positive, with 4 of 5 prior announcements followed by positive price reactions, but the latest KetoAir™ progress update saw a negative move, showing occasional divergence even on constructive news.
Over the last six months, Avalon has focused on KetoAir™ commercialization and strategic repositioning. Key milestones include a July 2025 cannabis breathalyzer development agreement, a July 2025 distribution deal with Saga Health, and the planned September 1, 2025 UK launch. A July 2025 Hong Kong CAR‑T/CAR‑NK patent broadened its IP. However, the Nov 21, 2025 8‑K highlighted Nasdaq listing compliance risks and an equity deficit, framing today’s operational progress against ongoing financial and listing challenges.
Market Pulse Summary
The stock moved -8.1% in the session following this news. A negative reaction despite operational progress fits a backdrop of financial strain and listing risk. Recent filings disclosed a stockholders’ equity deficit of $3,891,270 and net losses of $15.94 million over six months, alongside a history of unregistered share issuance. While prior KetoAir™ milestones sometimes coincided with gains, the price response has not been uniformly positive, suggesting sensitivity to balance sheet and Nasdaq compliance concerns.
Key Terms
fda-registered regulatory
ketosis medical
breath acetone concentration (brace) medical
nano-sensor technology technical
nanosensor-based diagnostic technologies technical
AI-generated analysis. Not financial advice.
FREEHOLD, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced a series of Q3 2025 advancements for KetoAir™, including expanded deployment, the launch of a first-responder metabolic health program, and entry into an international market.
Key Highlights
- Launched Holistic Health Reset Program with First Responders in Nevada
In August 2025, Avalon, together with Saga Health and SpecialtyHealth, Inc., launched the “Nevada POOL/PACT Holistic Health Reset” program for 50 first responders. The four-month wellness initiative targets metabolic, physical, and behavioral health improvements, supported by mutual accountability and structured guidance. Participants are using KetoAir™ for continuous daily monitoring of metabolic changes, helping them stay engaged and track progress throughout the program. - UK Launch of KetoAir™ Breathalyzer for Distribution and Sales
On September 1, 2025, Avalon began offering its FDA-registered breathalyzer device, KetoAir™, for purchase in the United Kingdom via www.KetoAir.uk. This milestone marks Avalon’s first international expansion of its marketing of the KetoAir™. - KetoAir™ Showcased at London Health Optimization Summit
Avalon presented KetoAir™ at the two-day London Health Optimization Summit on September 13th and 14th, 2025. During the event, attendees learned firsthand how KetoAir™ integrates into broader wellness and metabolic-health programs. - Mid-Program Results from First Responder Wellness Initiative
October mid-program data from the Nevada POOL/PACT Holistic Health Reset show individual improvements in metabolic health, which may be driven by better diet, exercise habits, sleep quality, and daily routines. KetoAir™ aims to play a role as a measurement and accountability tool, helping participants track daily ketone levels and stay aligned with their health goals.
“Our Q3 achievements reflect momentum for KetoAir™ as we expand into new markets and introduce solutions that meet the growing global demand for metabolic-health tools,” said Meng Li, Interim Chief Executive Officer and Chief Operating Officer of Avalon.”
KetoAir™ is a handheld breathalyzer designed for ketogenic health management (U.S. Food and Drug Administration registration number: 3026284320). It measures breath acetone concentration (BrAce), a key indicator of fat metabolism and ketosis. The KetoAir™ breathalyzer device is owned and manufactured by Qi Diagnostics Limited, a nanosensor-based diagnostic technologies company. Intended for users pursuing ketogenic diets for weight loss, athletic performance, or therapeutic purposes, the device utilizes nano-sensor technology to provide real-time insights. KetoAir™ is compatible with both Apple and Android devices and is available via the Apple App Store and Google Play Store.
For more information or to purchase KetoAir™, please visit www.ketoair.us.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a developer of precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. Avalon is currently marketing the KetoAir™ breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir™ is registered with the U.S. Food and Drug Administration as a Class I medical device. The Company also continues to focus on advancing its intellectual property portfolio through existing patent applications. In addition, Avalon owns and operates commercial real estate. For more information about Avalon, please visit www.avalon-globocare.com.
No Offer or Solicitation
This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any proxy, consent, authorization, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”).
Additional Information About the Proposed Merger for Investors and Shareholders
This communication relates to the proposed merger (the “proposed Merger”) of Avalon and YOOV Group Holding Limited (“YOOV”). In connection with the proposed Merger, Avalon has filed relevant materials with the U.S. Securities and Exchange Commission (the “SEC”), including a Registration Statement on Form S-4, as amended, that contains a preliminary prospectus and preliminary proxy statement of Avalon (the “proxy statement/prospectus”). This Registration Statement has not yet been declared effective and Avalon has filed or may file other documents regarding the proposed Merger with the SEC. This press release is not a substitute for the proxy statement/prospectus or for any other document that Avalon has filed or may file with the SEC in connection with the proposed Merger. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE PROPOSED MERGER. A definitive proxy statement/prospectus will be sent to Avalon’s stockholders. Investors and security holders will be able to obtain these documents (when available) free of charge from the SEC’s website at www.sec.gov. In addition, investors and stockholders should note that Avalon communicates with investors and the public using its website (https://www.avalon-globocare.com), the investor relations website (https://www.avalon-globocare.com/investors) where anyone will be able to obtain free copies of the proxy statement/prospectus and other documents filed by Avalon with the SEC, and stockholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed Merger.
Participants in the Solicitation
Avalon, YOOV and their respective directors and executive officers and other members of management and employees and certain of their respective significant stockholders may be deemed to be participants in the solicitation of proxies from Avalon and YOOV stockholders in respect of the proposed Merger. Information about Avalon’s directors and executive officers is available in Avalon’s Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on March 31, 2025. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holding or otherwise, has been and will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed Merger when they become available. Investors should read the definitive proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the SEC and Avalon as indicated above.
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates; however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of its products and the product’s ability to compete with other similar products. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission (the “SEC”), accessible through the SEC’s website (http://www.sec.gov), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. The Company disclaims any obligation to update forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. The contents of any website referenced in this press release are not incorporated by reference herein.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
FAQ
What did Avalon (ALBT) announce about KetoAir™ on Dec 1, 2025?
How is KetoAir™ being used in the Nevada POOL/PACT first‑responder program (ALBT)?
Is KetoAir™ FDA registered and who manufactures it for Avalon (ALBT)?
When did Avalon first offer KetoAir™ for sale in the UK (ALBT)?
What mid‑program results did Avalon report from the October 2025 Nevada study (ALBT)?
